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Abstract
Objective
The exact role of calcified neurocysticercotic lesions (CNLs) in epilepsy is yet unknown and
controversial. Although the relationship between CNLs, epilepsy and mesial temporal lobe
epilepsy with hippocampal sclerosis (MTLE-HS) has already been addressed, to our knowl-
edge, no study has actually provided strong statistical evidence, nor reported the ODDS
ratio for these associations. Therefore, we designed this case-control study to assess the
likelihood of having MTLE-HS versus other forms of epilepsy in the presence of CNLs.
Methods
In this case-control study we included 119 consecutive patients with epilepsy and 106 dis-
ease controls (headache) with previous CT scans. We subdivided cases into MTLE-HS and
other epilepsies. We used brain CT scans to define presence or absence of CNLs. After
exploratory analyses, we used logistic regression to analyze the association between
CNLs, epilepsy subgroups and disease controls.
Results
CNLs were found in 31.09% of cases and in 11.32% of controls (p<0.001). The initial analy-
sis comparing epilepsy versus controls revealed a significant association between CNLs
and epilepsy (OR = 5.32; 95%CI = 2.43-11.54; p<0.001). However, when we compared
MTLE-HS versus other epilepsies versus controls we confirmed that CNLs were associated
with MTLE-HS (OR = 11.27, 95%CI = 4.73-26.85; p<0.001) but other epilepsies were not.
We found no difference in the CNLs load and no difference in the location of the CNLs when
we compared patients with MTLE-HS, other epilepsies and disease controls.
Significance
The inclusion of controls allowed us to estimate the likelihood of having epilepsy in the pres-
ence of CNLs. We found that patients with CNLs were 11 times more likely to have MTLE-
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HS; however, the presence of CNLs did not change the odds of having other types of epi-
lepsy. These findings raise the possibility of neurocysticercosis playing a role in the patho-
physiology of MTLE-HS and need further confirmation in other series.
Introduction
Neurocysticercosis (NCC) infection is considered to be an important cause of epilepsy in devel-
oping countries [1, 2] and some studies suggest that up to a third of cases of epilepsy in
endemic areas may be attributed to NCC [3–5]. Although the relationship between acute
symptomatic seizures and NCC during its transitional stage has long been known [6], the exact
role of calcified neurocysticercotic lesions (CNLs) in epilepsy pathogenesis (with or without
hippocampal sclerosis (HS)) is yet unclear and controversial. Some studies suggest that there is
a clear association between CNLs and epilepsy in general [2,7,8]. Others indicate that CNLs are
not as inactive as previously thought, as indicated by perilesional edema, gliosis and contrast
enhancement seen in MRI and perfusion MRI studies. [1,9]. However, a previous study showed
that the presence of CNLs was not associate with the clinical and pathological findings nor
with postsurgical outcomes in patients with HS; thus suggesting that CNLs could represent a
coincidental pathology in the context of patients with HS and refractory seizures [10].
Mesial temporal lobe epilepsy (MTLE) is the most common form of epilepsy and HS is its
most common pathological substrate [11, 12]. The association between MTLE with HS
(MTLE-HS) and CNLs was also suggested by case reports and cross sectional analysis [2, 13,
14]. Some studies even suggest a causative role of CNLs in MTLE-HS [13, 15].
Although the relationship between CNLs, epilepsy and HS has been investigated by many
authors [2, 9, 15], to our knowledge, none provided strong statistical evidence, nor reported the
ODDS ratio for these associations. Given the controversy and lack of strong statistical evi-
dences, we designed a case-control study to assess the likelihood of MTLE-HS in the presence
of CNLs.
Materials and Methods
Ethics Statement
Our Research Ethics Committee (Comitê de Ética e Pesquisa- FCM/ Unicamp) approved the
study. We were exempted from having to obtain written informed consent from subjects due
to the retrospective nature of our study.
Participants
We conducted this case-control study at University of Campinas Hospital (HC-UNICAMP).
We analyzed data from 268 consecutive cases (with confirmed diagnosis of epilepsy [16]) from
our Epilepsy Clinics and 272 disease controls, who attended our Headache Clinics from July
2013 to September 2013 and excluded 315 that did not fulfill the study criteria (Recruitment
details are displayed in Fig 1). We included patients who attended our Headache Clinics as
“disease controls” (n = 106) and defined patients from our Epilepsy Clinics as “cases”
(n = 119). Since we included consecutive individuals, we did not match cases and controls for
gender and age. The rationale for choosing Headache Clinics patients as controls was the need
to have subjects without epilepsy from the same population, with similar socioeconomic back-
ground and who had already been submitted to a brain computed tomography (CT) scan. In
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addition, most of these patients had migraine or tension type headache, and even if the CNLs
were somewhat related to the headache, they did not have epilepsy.
Inclusion criteria for both groups were having a brain CT scan and being older than 15
years old. The rationale for choosing this imaging method was because CT is superior to MRI
scan to detect small calcified lesions [17]. However, all cases had also been submitted previ-
ously to a high resolution MRI with an epilepsy protocol for investigation of any underlying
epileptogenic lesion in our Epilepsy Clinics.
Exclusion criteria for both groups were having progressive central nervous system (CNS)
disease, CNS inflammatory disease, other diseases that may present with CNS calcifications
such as neurotuberculosis and neurotoxoplasmosis, CT or MRI lesions characteristic of active
NCC and patients with history of previously treated NCC. Patients with suspected CNS inflam-
matory disease at any point of their history, with inflammatory changes in the cerebral spinal
fluid or other positive immunological tests, as well as those with CT or MRI suggesting any
acute inflammatory lesions (i.e. contrast enhancement) were not included in this study. In the
“case” group, we excluded the following subjects: one patient with neurotoxoplasmosis, one
with Sturge-Weber Syndrome, three with tuberous sclerosis, four who were previously treated
for NCC and three who had active NCC in the past. The rationale for excluding those patients
was because we already know the relationship between acute symptomatic seizures and NCC
during its transitional stage and by excluding patients with previous history of active NCC we
aimed to minimize the influence of history of active NCC in our results (bias). From the “con-
trol group”, we excluded 13 patients who attended Headache Clinics and had also been diag-
nosed with epilepsy according to their medical records.
In summary, we included 119 cases and 106 controls with ages ranging from 16 to 84 years.
Fig 1. Flow diagram of enrolled cases and controls. Flow diagram showing on the left side how cases were selected and on right side how controls were
selected. As can be seen, the number of eligible patients that were excluded due to not having an available CT scan was the largest exclusion criteria in both
groups. CT = brain computed tomography scan, CNS = central nervous system, NCC = neurocysticercosis.
doi:10.1371/journal.pone.0131180.g001
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Data Collection and Classification
We collected the clinical data from each patient’s medical records. We then classified cases
based on their electroclinical syndrome and epilepsy etiology (Table 1) following International
League Against Epilepsy’s 2010 recommendation [18]. According to this classification, we were
able to define an electroclinical syndrome based on semiological data, typical electroencepha-
lography and MRI findings. Given our primary question was to evaluate the true relationship
between CNLs and MTLE-HS, we further divided cases into 2 subgroups: patients with
MTLE-HS (54 subjects) and patients with all other epilepsies (65 subjects). MTLE-HS was
defined as patient with the diagnosis of temporal lobe epilepsy in the presence of signs of HS
on MRI scans using an epilepsy protocol.
Brain CT Scan Analysis
We defined our primary variable of interest as the presence or absence of calcifications sugges-
tive of NCC. We extracted information regarding the presence or absence of small parenchy-
mal round calcifications from each radiological report. When radiological reports were not
available, we assigned a qualified neurologist to evaluate the scans. According to Del Brutto’s
diagnostic criteria for NCC [19], small parenchymal round calcifications are considered to be
highly suggestive of NCC and constitute a major diagnostic criterion. Given that our patients
also have one epidemiological criterion (NCC is endemic in Latin America) and one minor cri-
terion (clinical manifestations suggestive of NCC such as seizures), we may classify them as
probably having NCC. As CT scans were analyzed before this study, radiologists were
“blinded” to our objectives and methods. The neurologist who evaluated the remaining CT
scans was also blinded as to which group patients belonged.
If CNLs were present, we further classified patients according to number of CNLs (single or
multiple), side of CNLs (left, right or bilateral) and location (in the temporal lobe, extratem-
poral and unknown). Patients with multiple calcifications were classified as located in the tem-
poral lobe if at least one of the CNLs occurred in the temporal lobe, regardless the location of
other calcifications; the unknown category was assigned if the exact location of all CNLs was
not described in details on medical records (i.e. the scans were not available for review).
Table 1. Classification of cases according to electroclinical syndromes and epilepsy etiology based
on ILAE’s latest recommendation [18].
Patients with epilepsy (n = 119)
Electroclinical Syndromes
MTLE with hippocampal sclerosis (MTLE-HS) 54
All other syndromes except MTLE-HS 65
Unknown 25
Stroke 11
Tumor 11
Malformation of cortical development 9
Juvenile myoclonic epilepsy 4
Infection 1
Gelastic seizures with hypothalamic hamartoma 2
Epilepsy with GTCS alone 1
Trauma 1
aAbbreviations: ILAE = International League Against Epilepsy; MTLE-HS = mesial temporal lobe epilepsy
with hippocampal sclerosis; GTCS = generalized tonic-clonic seizures.
doi:10.1371/journal.pone.0131180.t001
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MTLE-HS and Presence of CNLs
Patients with both CNLs and MTLE-HS were also divided into subgroups according to the side
of occurrence of CNLs in relation to the ide of HS (bilateral, ipsilateral and contralateral).
Statistical Analysis
We performed data analysis using SAS System (Statistical Analysis System, version 9.2, SAS
Institute Inc., Cary, NC, USA) for Windows. First, we ran an exploratory analysis, measuring
frequencies for categorical data and descriptive statistics for quantitative data. We compared
data between cases and controls using Mann-Whitney-U tests for numerical variables and chi-
square tests for categorical variables. We subsequently performed both univariate (controls
versus epilepsy) and multivariate (controls versus MTLE-HS versus other epilepsies) logistic
regression analysis to investigate the relationship between CNLs and MTLE-HS and between
CNLs and other epilepsies. Significance was defined as p<0.05 for all analysis.
Results
Baseline Information
From the original sample of 268 cases and 272 controls we ultimately included 119 cases (77
women, age = 44.49 ± 13.43 years; 95%CI) and 106 controls (78 women, age = 51.27 ± 15.46
years; 95%CI). The demographic distribution of cases and controls can be seen on Table 2.
Controls were found to be significantly older (p<0.001) than cases when a Mann-Whitney-U
test was performed; however, both groups were similar in terms of gender distribution
(p = 0.15). Detailed information for each patient and disease-controls subjects can be found in
the Supporting Information S1 Table.
Comparison between Epilepsy versus Controls
We identified CNLs in 31.09% of our cases. It is of notice that 11.32% of controls also had
CNLs despite the absence of symptoms suggestive of acute phase of NCC in the past, such as
seizures, on their medical history. This difference was significant (p<0.001). In general, CNLs
were also more frequent in women than men (27.1% versus 10%; p = 0.004). When comparing
all subjects with CNLs with all those without CNLs, there was no difference regarding their age
(50.86 years ± 10.83 versus 46.8 years ± 15.62; p = 0.10).
Initially, we used a binary logistic regression to compare cases and controls using presence
or absence of CNLs as the dependent variable adjusted for age and gender. We found that the
presence of epilepsy was associated with CNLs (OR = 5.32; 95%CI = 2.43–11.54; p<0.001),
Table 2. Demographics of cases and controls.
Cases Controls p value
Gender p = 0.15 (Chi-square)
Male 42 28
Female 77 78
Mean age (± SD) 44.49 (±13.43) 51.27 (±15.46) p<0.001 (Mann-whitney)
Calcification 37 (31.09%) 12 (11.32%) p<0.001 (Chi-square)
When comparing patients with MTLE-HS and other epilepsies, we observed no difference regarding their gender distribution (68.52% women on
MTLE-HS versus 61.54%; p = 0.43), but found that patients with MTLE-HS were older (48.87 years ± 12.6 versus 40.85 years ± 13.1; p<0.001).
doi:10.1371/journal.pone.0131180.t002
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meaning that the presence of calcification increases in 5 times the chance of having epilepsy in
general.
Sub-Analysis (MTLE-HS versus Other Epilepsies versus Controls)
The sub-analysis aimed to compare patients with MTLE-HS (54 cases), controls (106 subjects)
and patients with other epilepsies (65 cases). Using chi-square test on a 3x2 contingency table,
we found that patients with MTLE-HS had a higher frequency of CNLs (28/54, 51.85%) when
compared to both controls (12/106, 11.32%) and patients with other epilepsies (9/65, 13.85%)
(p<0.001) as seen on Fig 2.
Subsequently, we performed a multinomial logistic regression using the same dependent
variable (presence or absence of CNLs) with these 3 groups: MTLE-HS; other epilepsies and
controls. After adjusting the analysis for age and gender, we observed that CNLs were associ-
ated with MTLE-HS compared to controls (OR = 11.27, 95%CI = 4.73–26.85; p<0.001), CNLs
were associated with MTLE-HS compared to other epilepsies (OR = 5.77, 95%CI = 2.26–14.12;
p<0.001)) and that CNLs were not associated with other epilepsies as compared to controls
(OR = 1.95, 95%CI = 0.73–5.2; p = 0.18). For the association between CNLs and MTLE-HS the
statistical power was higher than 90% (Table 3). These findings confirmed that neurocysticer-
cotic calcifications were more frequent in patients who have MTLE-HS than in both controls
Fig 2. Total Number of Subjects with calcified neurocysticercotic lesions on CT scans. This graph shows the percentage of subjects with calcified
neurocysticercotic lesions in each subgroup (MTLE with HS, other epilepsies, disease controls). MTLE-HS = Mesial temporal lobe epilepsy with hippocampal
sclerosis, CNLs = Calcified neurocysticercotic lesions.
doi:10.1371/journal.pone.0131180.g002
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and patients with other epilepsies; it also indicates that patients with CNLs were 11 times more
likely to have MTLE-HS.
Sub-Analysis (MTLE-HS versus Location of CNLs)
In this sub-analysis, we included only cases and controls with CNLs and divided them in 3
groups: MTLE-HS (n = 28), other epilepsies (n = 9) and controls (n = 12). We analyzed
whether there were any differences in location of CNLs (temporal, extratemporal, unknown)
amongst those 3 groups. We did not find a significant difference (p = 0.58) in CNLs location
between them as seen in Fig 3.
We did not find differences in CNLs load between these 3 groups (p = 0.14), as illustrated in
Fig 4. The analysis of the CNLs side comparing to the side of HS showed that 21% of the CNLs
were ipsilateral to the side HS, 17% were contralateral to the HS side and 62% had bilateral
CNLs (including in this last group one patient that had bilateral HS).
Discussion
We found an association between neurocysticercotic calcifications and MTLE-HS. Our data
showed that the association between CNLs and epilepsy in general is much influenced by
patients with MTLE-HS (45.4% in our cohort); since the exclusion of MTLE-HS from the
model/analysis yielded non-significant association between CNLs and other types of epilepsy.
The frequency of CNLs in our study is seemingly high (31% for cases overall, and 11% for
disease controls). However, the frequency of CNLs in patients with epilepsy has been high in
studies from the same region [2]. In addition, a recent study that invited 248 volunteers
(age> 60 years) to perform CT or MRI scans also detected CNLs in 11% of these individuals
(only 4 of these had epilepsy) [14].
Our findings are similar to that of Velasco et al [2], showing an association between CNLs
and HS and suggesting that NCC is possibly a form of initial precipitating injury (IPI), rather
than a major cause of epilepsy. The main difference between our study and that of Velasco et al
[2] and others [14, 20, 21], is the inclusion of a disease control group, thus, providing stronger
evidence for these associations, at least in the context of a hospital based population.
We also found a higher frequency of CNLs amongst women, as seen in previous studies [22,
23, 24]. The possible cause of this finding is still unknown.
We discuss here four possible explanations for our findings, as suggested previously in the
literature [13, 15]. The first would be coincidence. The second possible explanation would be
that NCC and MTLE-HS are associated, but are not causally related (e.g. due to a third unre-
lated factor, such as poor socioeconomic background). Third, NCC may be a direct cause of
MTLE-HS or epilepsy. Fourth, the association between NCC and MTLE-HS is as part of the
epileptogenic process (trigger) but not a direct causative factor.
The first theory claims that since both diseases are relatively common entities in endemic
areas, they just happen to appear in the same patient as a coincidence. We do recognize that in
some patients that might be the case, but we believe that this theory seems unable to explain
the very high frequency of CNLs in patients with MTLE-HS found in our study (51.85%) or in
Table 3. Multinomial logistic regression model for association with CNLs.
Odds ratio 95% CI p value
MTLE-HS versus controls 11.27 4.73–26.85 <0.0001
MTLE-HS versus other epilepsies 5.77 2.26–14.71 0.0002
Other epilepsies versus controls 1.95 0.73–5.20 0.1806
doi:10.1371/journal.pone.0131180.t003
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other studies: 17.7% and 37.2% in two studies of MTLE-HS patients submitted to surgery [10,
25] or 35.6% in a retrospective cohort [26].
The second theory does not deny a correlation between NCC and MTLE-HS, but it claims
that there is no causative association between both: a third variable would be implicated in the
pathophysiology of both. In statistics, correlation does not mean causation. In the case of NCC
and MTLE-HS, for example, low economic status or genetic susceptibility to both conditions
could lead to this association [15]. Although both groups (cases and controls) in our study had
the same socioeconomic background, we cannot rule out the possibility of poverty or genetic
susceptibility being the third variable to explain both NCC and MTLE-HS in our series.
The third theory states that MTLE-HS may be caused by direct inflammation and structural
damage to the hippocampi or cortex by the acute phase of cysticerci located in the vicinity.
This might be true for some specific cases, but probably does not explain all of them. For exam-
ple, there are case reports of patients with a cysticercus in the hippocampus with MTLE-HS
[27, 28]. Thus, we do not think this is the most important mechanism by which NCC could
cause MTLE-HS, because in patients with MTLE-HS and NCC the calcified lesions are not nec-
essarily located in the temporal lobes, as we demonstrated earlier in a different series of patients
in our center [29]. In that study [29], like in the present study, we found no relationship
Fig 3. Location of neurocisticercotic calcifications in each group. This graph shows the percentage of subjects with calcifications located in the temporal
lobe (Temporal), outside the temporal lobe (extratemporal) and unknown in each subgroups (MTLE-HS, other epilepsies, disease controls). There were no
significant group differences considering the presence of calcifications in the temporal lobes. (p = 0.58) MTLE-HS = Mesial temporal lobe epilepsy with
hippocampal sclerosis.
doi:10.1371/journal.pone.0131180.g003
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between localization of CNLs (temporal or extra-temporal) and seizure semiology (MTLE or
other types of epilepsy).
The fourth theory suggests the presence of NCC could work as an IPI that would lead to HS,
via multiple mechanisms, and then HS itself would cause chronic seizures, and frequently
refractory epilepsy. There is evidence that some specific kinds of lesions or aggressions may
cause mesial temporal lobe damage and as a consequence lead to HS, which would then cause
MTLE [30, 31]. These aggressions are known as IPIs [31]. The most studied IPIs are prolonged
febrile seizures, neonatal hypoxia, status epilepticus, trauma and meningoencephalitis [32].
This theory suggests that one plausible explanation for the association we have found is that
NCC most likely represents one IPI in patients with predisposition to have seizures and there-
fore to develop MTLE-HS. Clinical or subclinical inflammation on the acute phase of infection
would damage or aggravate a previously injured or predisposed hippocampus. The presence of
inflammation is widely accepted [33] and a MRI perfusion study [1] suggests that even after
resolution of the acute phase, with the formation of CNLs, there may still be inflammation
induced by the acute phase. The CNLs would function both as a marker of previous damage to
the hippocampus and as an active injury [34]. Another possible mechanism of epileptogenesis,
Fig 4. Number of neurocisticercotic calcifications in each group. This graph shows the percentage of subjects with single or multiple calcifications in
each subgroup (MTLE-HS, other epilepsies, disease controls). There were no significant group differences regarding the load of lesions (p = 0.14).
MTLE-HS = Mesial temporal lobe epilepsy with hippocampal sclerosis.
doi:10.1371/journal.pone.0131180.g004
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according to some authors, would be the degenerating cysts leading to the development of elec-
trical activity in the hippocampi through the phenomena of kindling, interictal discharge or
even subclinical seizures [13]. A previous study comparing patients with MTLE-HS with or
without CNLs found no difference in their post-surgical prognosis [10], which in our opinion
(although not directly proven by the present study) further supports the notion of NCC as an
IPI, given the presence of CNLs after surgery (even in the hemisphere contralateral to the surgi-
cal resection) would not influence post-surgical outcome. This goes along with our finding that
NCC is more associated with HS, and hence MTLE-HS, than with other epilepsies in the con-
text of our series. Another circumstantial evidence that NCC may be an IPI for MTLE-HS is
the higher prevalence of MTLE-HS in developing countries, where NCC is endemic, compared
to developed countries [35, 36].
Limitations
There are some limitations to our study: our controls were not healthy volunteers, as it would
be unethical to submit healthy controls to unneeded radiation exposure. Therefore, it is possi-
ble that the frequency of CNLs differs between a healthy population and controls selected from
a Headache Clinics [37]. However, as discussed above, the rate of CNLs in our disease controls
was similar to that reported by Dell Bruto et al. [14].
Another limitation is that 43 out of 106 controls were using antiepileptic drugs, which raises
the possibility that some of them did not present with seizures simply because they were
already being treated.
Another limitation was that all patients with CNLs were considered to have NCC despite
not fulfilling criteria for definitive diagnosis. According to the most recent diagnostic criteria
[19], those patients would be considered to have a probable diagnosis of NCC based on the
findings of highly suggestive lesions on CT scan plus suggestive clinical manifestations and liv-
ing in endemic area. Additionally, our study is retrospective and uses data that had already
been described in medical charts or radiological reports. Another limitation is that not all con-
trols had undergone MRI scans, which might have shown HS even in asymptomatic (e.g. with-
out epilepsy) patients [38]. In addition, 45.8% of 119 cases had MTLE-HS probably due to a
referral bias, as our institution is a reference center in its region for the treatment of refractory
epilepsy. That said, it might not be feasible to prove or disprove the association between CNLs
and MTLE-HS in a population-based study, given the relatively low prevalence of the former
in the overall population.
In conclusion, our study showed a significant association between CNLs and MTLE-HS and
indirectly suggests that NCC may acts as an IPI in patients with predisposition to develop HS
or to have seizures. However, our data does not support the association between NCC and
other types of epilepsy. It is important to note that these findings cannot be extrapolated to the
general population, first, because it is a series from a tertiary center, and second, because of the
heterogeneity of the other subgroups in our study. In this article, we review several different
mechanisms by which NCC and MTLE-HS might be associated. We believe that the relation-
ship between NCC and MTLE-HS is complex and probably results from the combination of all
possible mechanisms discussed herein.
Given the controversy and lack of strong statistical evidences addressing the relationship
between CNLs, epilepsy and HS the results reported herein provide important statistical evi-
dence regarding the risk of epilepsy in the presence of CNLs. We found that the presence of
CNLs increases in 11 times the likelihood of having epilepsy with HS. This finding is important
for the understanding of the pathophysiology of NCC and HS and the concept of dual pathol-
ogy. The decision of considering the presence of CNLs in a patient with MTLE-HS as a possible
Neurocysticercosis and Hippocampal Sclerosis
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IPI, and not as a dual pathology, may have implications in treatment and prognosis for patients
with CNLs and HS.
Statistical Analysis
Statistical analysis was conducted by Dr. Morita (Department of Neurology), Dr. Cendes
(Department of Neurology) and Biostatistical Support Group from FCM—University of
Campinas.
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S1 Table. Clinical and demographic data for all patients and disease-controls.
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